Angus C. Russell
CIK 1534002 · last filed 2026-07-02
Angus C. Russell is a corporate insider who has filed 68 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing, for LCTX, was dated Jul 2, 2026. Across all open-market trades the lifetime net is +$844.2K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $100.9K across reported positions. 16 SEC filings were submitted jointly with CROFF ENTERPRISES INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$100.9K
7
68
$844.2K
Filer Profile
3280 BAYSHORE BOULEVARD
BRISBANE, CA 94005
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LCTX | Director | 87,500 | $1.01 | $88.4K | -$14.0K | 8 | 2026-07-02 |
| GPCR | Director | — | $38.66 | — | $0 | 3 | 2026-06-18 |
| Revance Therapeutics, Inc. (RVNC) Delisted | Director | 0 | $3.65 | $0 | $100.7K | 14 | 2025-02-06 |
| TXMD | Director | 5,792 | $2.16 | $12.5K | $422.7K | 15 | 2022-10-03 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 0 | $0.34 | $0 | -$6.7K | 13 | 2020-11-16 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 67,500 | — | — | $191.5K | 5 | 2018-07-03 |
| QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Director | 5,114 | — | — | $150.0K | 3 | 2013-11-13 |
Recent Filings
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2026-06-18 | GPCR | Grant (A) | — | $0 | EDGAR |
| 2025-07-02 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2025-06-25 | GPCR | Grant (A) | — | $0 | EDGAR |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −51,506 | -$133.2K | EDGAR |
| 2024-08-28 | GPCR | Grant (A) | — | $0 | EDGAR |
| 2024-07-03 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2024-05-03 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2023-07-03 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2023-05-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +3,534 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.